56 research outputs found
Comparison of fractional excretion of sodium, uric acid and urea nitrogen in diagnosis of pediatric acute prerenal failure
Background and aim: various factors, in terms of faster diagnosis of acute renal failure have been studied so far, but these studies have been done mostly on adults. Therefore, in this paper we made a comparison of fractional excretion of sodium (FeNa), uric acid (FeUa) and urea nitrogen (FeU) in acute prerenal failure in children to find out which one is more sensitive in diagnosis of acute prerenal failure. Material and Methods: In a cross-sectional study, 5 CC blood was taken from 29 children of 1 month to 15 years old, diagnosed with acute pre-renal failure; the amount of creatinine, sodium, uric acid and urea nitrogen was measured in their plasma. After taking a standard urine specimen, all the mentioned items were measured in patients' urine and put into the formula of FeNa, FeUa and FeU and compared. Results: In this study, 75.8% FeU, 68.9% FeUa and 58.6% FeNa are agreeable to prerenal criteria and the most sensitivity is assigned to FeU. Among the three groups, FeNa is more affected by treatment with diuretic. The difference between FeNa in the receiver group of normal saline and the receiver group of diuretic is more than those groups which did not receive any. Conclusion: Fractional excretion of urea nitrogen in children, especially in the receivers of diuretic is more sensitive in diagnosis of acute prerenal failure. Moreover, this index is more sensitive in diagnosis of acute prerenal failure than the other indexes
Effects of FK506 on Hippocampal CA1 Cells Following Transient Global Ischemia/Reperfusion in Wistar Rat
Transient global cerebral ischemia causes loss of pyramidal cells in CA1 region of hippocampus. In this study, we investigated the neurotrophic effect of the immunosuppressant agent FK506 in rat after global cerebral ischemia. Both common carotid arteries were occluded for 20 minutes followed by reperfusion. In experimental group 1, FK506 (6 mg/kg) was given as a single dose exactly at the time of reperfusion. In the second group, FK506 was administered at the beginning of reperfusion, followed by its administration intraperitoneally (IP) 6, 24, 48, and 72 hours after reperfusion. FK506 failed to show neurotrophic effects on CA1 region when applied as a single dose of 6 mg/kg. The cell number and size of the CA1 pyramidal cells were increased, also the number of cell death decreased in this region when FK506 was administrated 48 h after reperfusion. This work supports the possible use of FK506 in treatment of ischemic brain damage
Cytokine Profiles and Cell Proliferation Responses to Truncated ORF2 Protein in Iranian Patients Recovered from Hepatitis E Infection
Background.The aim of this study was to evaluate hepatitis E virus (HEV) specific cellular immune responses to truncated ORF2
protein in Iranian patients recovered from HEV infection. Information about HEV-specific immune responses could be useful in
finding an effective way for development of HEV vaccine. Methods. A truncated formof HEVORF2 protein containing amino acids
112-608 was used to stimulate peripheral blood mononuclear cells (PBMCs) separated from HEV-recovered and control groups.
Finally, the levels of four cytokines, IFN
Fertility disorder associated with celiac disease in males and females: fact or fiction?
Abstract Aim: The association between celiac disease and infertility is controversial in the literature
The global burden of cancer attributable to risk factors, 2010-19 : a systematic analysis for the Global Burden of Disease Study 2019
Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.Peer reviewe
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation
Autoimmune diseases and pregnancy: a narrative review
Background and Aims: In recent years, great strides have been made in the field of autoimmune diseases. In this article, we review the autoimmune diseases in pregnancy.Materials and Methods: The findings of the current narrative review article were obtained through searching on valid medical sites including PubMed, Scopus, Web of Science and using the Google Scholar search engine without time limit until the end of 2021, with the "autoimmune disease and pregnancy" keywords.The inclusion criteria were English-language articles in the field of autoimmune diseases with more prevalence or complications in pregnancy included rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, antiphospholipid syndrome, Sjogren's syndrome, systemic sclerosis, and systemic vasculitis. Exclusion criteria were lack of access to the full article, documentation including commentary and letter to the editor. The results obtained from the title and abstract of the articles were checked by two evaluators.Results: These diseases show different reactions to pregnancy, so that some are cured, others remain unchanged, and several different types of it may worsen during this period. The reaction of autoimmune diseases to the hormonal and immunological changes of pregnancy shows the different pathophysiology of each disease. Proper consultation with relevant experts is the right solution for these people.Conclusion: Women should be informed about the possible risks of this type of pregnancy and the use of some medications during this period. Because the activity of this disease during pregnancy can be problematic, it is necessary to have a rheumatologist during pregnancy and even after, along with obstetrician
Vitamin D: Is There a New Era?
Background: In recent decades, much interest has been focused on investigating new roles of vitamin D in human body beyond the mineral-ion homeostasis. Methods: By searching medical databases such as PubMed, over 16000 articles were found which have been published since 2000 on novel aspects of vitamin D in health and diseases. Results: Of great interest was the effects of vitamin D on decreasing the risk of several chronic illnesses, including common cancers, autoimmune, infectious, and cardiovascular diseases. In this review, the new roles of vitamin D that have recently been investigated were addressed. Conclusions: Due to the vast prevalence of vitamin D deficiency worldwide, it seems that time has come to conduct well-designed clinical trials and meta-analysis to explore the effectiveness of vitamin D supplementation in treatment of common diseases. Finally, the progression in cellular and molecular methods and technology will shed new lights on vitamin D roles in health and disease
- …